Publikationen 2018

Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, Kreuzer C, Laufer D, Mengel R, Mottaghy FM, Müller HW, Müller SC, Ost E, Rahbar K, Reifenhäuser W, Schäfers M, Schlenkhoff C, Schmidt M, Schmidt-Wolf I, Wildenhain C, Zimmer B, Essler M.
Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein.
Urologe A. 2018 Jun;57(6):709-713.
doi: 10.1007/s00120-018-064-2. Review. German. PubMed PMID: 29671080.

Al-Monajjed R, Arsov C, Albers P.
[Prostate cancer screening: controversies and suggested solutions]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Dec;61(12):1544-1550.
doi: 10.1007/s00103-018-2840-x. Review. German. PubMed PMID: 30397721.

Al-Monajjed R, Arsov C, Albers P.
[Effect of performing a single PSA screening : The CAP trial].
Urologe A. 2018 Sep;57(9):1137-1138.
doi: 10.1007/s00120-018-0678-3. German. PubMed PMID: 29796696.

Albers P, Weytjens B, De Mot R, Marchal K, Springael D.
Molecular processes underlying synergistic linuron mineralization in a triple-species bacterial consortium biofilm revealed by differential transcriptomics.
Microbiologyopen. 2018 Apr;7(2):e00559.
doi: 10.1002/mbo3.559. Epub 2018 Jan 3. PubMed PMID: 29314727; PubMed Central PMCID: PMC5911999.

Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C.
Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Eur Urol. 2019 Feb;75(2):310-318.
doi: 10.1016/j.eururo.2018.07.031. Epub 2018 Aug 3. PubMed PMID: 30082150.

Bagrodia A, Albers P.
Editorial comment.
Curr Opin Urol. 2018 Sep;28(5):433-434.
doi: 10.1097/MOU.0000000000000524. PubMed PMID: 30044318.

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators.
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Ann Oncol. 2018 Feb 1;29(2):361-369.
doi: 10.1093/annonc/mdx692. PubMed PMID: 29077785.

Boegemann M, Arsov C, Hadaschik B, Herkommer K, Imkamp F, Nofer JR, Gerß J, Albers P, Semjonow A.
Discordant prostate specific antigen test results despite WHO assay standardization.
Int J Biol Markers. 2018 Aug;33(3):275-282.
doi: 10.1177/1724600818754750. Epub 2018 May 8. PubMed PMID: 29734838.

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
Acta Oncol. 2018 Apr;57(4):491-497.
doi: 10.1080/0284186X.2017.1369565. Epub 2017 Aug 30. PubMed PMID: 28853615.

Cash H, Steiner U, Heidenreich A, Klotz T, Albers P, Melchior S, Martus P, Fuller F, Magheli A, Hinz S, Kempkensteffen C, Miller K; PRINCE investigators.
Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE).
BJU Int. 2018 Nov;122(5):774-782.
doi: 10.1111/bju.14239. Epub 2018 May 6. PubMed PMID: 29633515.

Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F, De Giorgi U, Fedyanin M, Oing C, Haugnes HS, Hentrich M, Fankhauser C, Gillessen S, Beyer J.
Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry.
J Clin Oncol. 2018 Oct 4:JCO1800210.
doi: 10.1200/JCO.18.00210. [Epub ahead of print] PubMed PMID: 30285559. 

Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, Looijenga LHJ.
Testicular cancer.
Nat Rev Dis Primers. 2018 Oct 5;4(1):29.
doi: 10.1038/s41572-018-0029-0. Review. PubMed PMID: 30291251.

Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN.
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.
Front Oncol. 2018 Nov 19;8:463.
doi: 10.3389/fonc.2018.00463. eCollection 2018. PubMed PMID: 30510914; PubMed Central PMCID: PMC6252384.  

Dimitroulis P, Rabenalt R, Nini A, Hiester A, Esposito I, Schimmöller L, Antoch G, Albers P, Arsov C.
Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy-Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required?
J Urol. 2018 Nov;200(5):1030-1034.
doi: 10.1016/j.juro.2018.05.002. Epub 2018 May 5. PubMed PMID: 29733837. 

Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Araúzo-Bravo MJ, Santourlidis S.
Author Correction: Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis.
Sci Rep. 2018 Apr 11;8(1):6051.
doi: 10.1038/s41598-018-23158-z. PubMed PMID: 29643401; PubMed Central PMCID: PMC5895801. 

Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Araúzo-Bravo MJ, Santourlidis S.
Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis.
Sci Rep. 2018 Feb 22;8(1):3477.
doi: 10.1038/s41598-018-21932-7. Erratum in: Sci Rep. 2018 Apr 11;8(1):6051. PubMed PMID: 29472622; PubMed Central PMCID: PMC5823913. 

Fenner M, Oing C, Dieing A, Gauler T, Oechsle K, Lorch A, Hentrich M, Kopp HG, Bokemeyer C, Honecker F.
Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
J Cancer Res Clin Oncol. 2018 Sep 19.
doi: 10.1007/s00432-018-2752-z. [Epub ahead of print] PubMed PMID: 30232558. 

Goethe VE, Angerer H, Dinkel A, Arsov C, Hadaschik B, Imkamp F, Gschwend JE, Herkommer K.
Concordance and Discordance of Sexual Identity, Sexual Experience, and Current Sexual Behavior in 45-Year-Old Men: Results From the German Male Sex-Study.
Sex Med. 2018 Dec;6(4):282-290.
doi: 10.1016/j.esxm.2018.08.001. Epub 2018 Sep 28. PubMed PMID: 30274908; PubMed Central PMCID: PMC6302220.  

Gschwend JE, Albers P, Bögemann M, Goebell P, Heidenreich A, Klier J, König F, Machtens S, Pantel K, Thomas C.
[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].
Urologe A. 2018 Jan;57(1):34-39.
doi: 10.1007/s00120-017-0533-y. German. PubMed PMID: 29071398.

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M.
Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30737-1.
doi: 10.1016/j.eururo.2018.09.047. [Epub ahead of print] PubMed PMID: 30337060. 

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.
Ann Oncol. 2018 Aug 1;29(8):1658-1686.
doi: 10.1093/annonc/mdy217. PubMed PMID: 30113631.

Hölscher AS, Schulz WA, Pinkerneil M, Niegisch G, Hoffmann MJ.
Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Clin Epigenetics. 2018 Jan 4;10:1.
doi: 10.1186/s13148-017-0434-3. eCollection 2018. PubMed PMID: 29312470; PubMed Central PMCID: PMC5755363.

Kaletsch A, Pinkerneil M, Hoffmann MJ, Jaguva Vasudevan AA, Wang C, Hansen FK, Wiek C, Hanenberg H, Gertzen C, Gohlke H, Kassack MU, Kurz T, Schulz WA, Niegisch G.
Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Clin Epigenetics. 2018 Jul 31;10(1):100.
doi: 10.1186/s13148-018-0531-y. PubMed PMID: 30064501; PubMed Central PMCID: PMC6069857.

Klingebiel M, Ullrich T, Rabenalt R, Albers P, Antoch G, Schimmöller L.
MRT-(in-bore)-Biopsie zur sicheren Detektion kleiner oder ungünstig gelegener Prostatakarzinome bei negativer MRT/Ultraschall-Fusionsbiopsie.
Rofo. 2018 Nov;190(11):1067-1069.
doi: 10.1055/a-0620-8875. Epub 2018 Jun 6. German. PubMed PMID: 29874701.

Lakes J, Lusch A, Nini A, Albers P.
Retroperitoneal lymph node dissection in the setting of elevated markers.
Curr Opin Urol. 2018 Sep;28(5):435-439.
doi: 10.1097/MOU.0000000000000535. PubMed PMID: 30004909.

Lorch A.
Management of Refractory Germ Cell Cancer.
Am Soc Clin Oncol Educ Book. 2018 May 23;(38):324-329.
doi: 10.1200/EDBK_201189. Review. PubMed PMID: 30231348. 

Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD.
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2019 Feb;17(1):7-14.e3.
doi: 10.1016/j.clgc.2018.09.008. Epub 2018 Sep 13. PubMed PMID: 30292628.

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium Group.
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.
lin Genitourin Cancer. 2018 Apr;16(2):e483-e490.
doi: 10.1016/j.clgc.2017.10.012. Epub 2017 Nov 1. PubMed PMID: 29158079.

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
Eur Urol Focus. 2018 Dec;4(6):937-945.
doi: 10.1016/j.euf.2017.03.011. Epub 2017 Mar 31. PubMed PMID: 28753879; PubMed Central PMCID: PMC5626651. 

Nettersheim D, Berger D, Jostes S, Skowron M, Schorle H.
Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors.
J Cell Mol Med. 2019 Jan;23(1):670-679.
doi: 10.1111/jcmm.13971. Epub 2018 Nov 20. PubMed PMID: 30460772; PubMed Central PMCID: PMC6307807.  

Niegisch G.
Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?
Transl Androl Urol. 2018 Dec;7(Suppl 6):S744-S746.
doi: 10.21037/tau.2018.08.16. PubMed PMID: 30687614; PubMed Central PMCID: PMC6323284.

Niegisch G, Gerullis H, Lin SW, Pavlova J, Gondos A, Rudolph A, Haas G, Hennies N, Kramer MW.
A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
J Cancer. 2018 Mar 29;9(8):1337-1348.
doi: 10.7150/jca.23162. eCollection 2018. PubMed PMID: 29721042; PubMed Central PMCID: PMC5929077.

Niegisch G, Nini A, Michalski R, Henn A, Mally D, Albers P, Rabenalt R.
Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion.
Urol Int. 2018;101(2):224-231.
doi: 10.1159/000491588. Epub 2018 Jul 25. PubMed PMID: 30045033.

Nilius V, Killer MC, Timmesfeld N, Schmitt M, Moll R, Lorch A, Beyer J, Mack E, Lohoff M, Burchert A, Neubauer A, Brendel C.
High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion.
Oncoimmunology. 2018 Feb 16;7(5):e1423169.
doi: 10.1080/2162402X.2017.1423169. eCollection 2018. PubMed PMID: 29721375; PubMed Central PMCID: PMC5927517.

Nini A, Konieczny M, Winter C, Lusch A, Krauspe R, Albers P.
Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series.
Urol Oncol. 2018 Feb;36(2):82.e1-82.e5.
doi: 10.1016/j.urolonc.2017.10.016. Epub 2017 Nov 10. PubMed PMID: 29129354.

Noldus J, Niegisch G, Pycha A, Karl A.
[Radical cystectomy and urinary diversion-what is important ?].
Urologe A. 2018 Jun;57(6):673-678.
doi: 10.1007/s00120-018-0648-9. Review. German. PubMed PMID: 29696301.

Oing C, Lorch A.
The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
Oncol Res Treat. 2018;41(6):365-369.
doi: 10.1159/000489135. Epub 2018 May 8. PubMed PMID: 29843143.

Okhunov Z, Yoon R, Lusch A, Spradling K, Suarez M, Kaler KS, Patel R, Hwang C, Osann K, Huang J, Lee T, Landman J.
Evaluation and Comparison of Contemporary Energy-Based Surgical Vessel Sealing Devices.
J Endourol. 2018 Apr;32(4):329-337. 
doi: 10.1089/end.2017.0596. PubMed PMID: 29463122; PubMed Central PMCID: PMC5909080.

Osei Kuffour E, Schott K, Jaguva Vasudevan AA, Holler J, Schulz WA, Lang PA, Lang KS, Kim B, Häussinger D, König R, Münk C.
USP18 (UBP43) Abrogates p21-Mediated Inhibition of HIV-1.
J Virol. 2018 Sep 26;92(20). pii: e00592-18.
doi: 10.1128/JVI.00592-18. Print 2018 Oct 15. PubMed PMID: 30068654; PubMed Central PMCID: PMC6158439.

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I, Théodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS.
Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8].
Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30931-X.
doi: 10.1016/j.eururo.2018.11.032. [Epub ahead of print] PubMed PMID: 30502102.

Pierorazio PM, Albers P, Black PC, Tandstad T, Heidenreich A, Nicolai N, Nichols C.
Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary.
Eur Urol. 2018 Jun;73(6):899-907.
doi: 10.1016/j.eururo.2017.12.030. Epub 2018 Jan 12. Review. PubMed PMID: 29338978.

Pinkerneil M, Hoffmann MJ, Niegisch G.
Epigenetic Treatment Options in Urothelial Carcinoma.
Methods Mol Biol. 2018;1655:289-317.
doi: 10.1007/978-1-4939-7234-0_21. PubMed PMID: 28889393.

Sathe A, Chalaud G, Oppolzer I, Wong KY, von Busch M, Schmid SC, Tong Z, Retz M, Gschwend JE, Schulz WA, Nawroth R.
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
PLoS One. 2018 Jan 22;13(1):e0190854.
doi: 10.1371/journal.pone.0190854. eCollection 2018. PubMed PMID: 29357370; PubMed Central PMCID: PMC5777650.

Schlütermann D, Skowron MA, Berleth N, Böhler P, Deitersen J, Stuhldreier F, Wallot-Hieke N, Wu W, Peter C, Hoffmann MJ, Niegisch G, Stork B.
Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
Urol Oncol. 2018 Apr;36(4):160.e1-160.e13.
doi: 10.1016/j.urolonc.2017.11.021. Epub 2017 Dec 21. PubMed PMID: 29276062.

Schönberger S, van Beekum C, Götz B, Nettersheim D, Schorle H, Schneider DT, Casati A, Craveiro RB, Calaminus G, Dilloo D.
Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
J Cell Mol Med. 2018 Jan;22(1):568-575.
doi: 10.1111/jcmm.13344. Epub 2017 Sep 22. PubMed PMID: 28941150; PubMed Central PMCID: PMC5742680.

Skowron MA, Melnikova M, van Roermund JGH, Romano A, Albers P, Thomale J, Schulz WA, Niegisch G, Hoffmann MJ.
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.
Int J Mol Sci. 2018 Feb 16;19(2). pii: E590.
doi: 10.3390/ijms19020590. PubMed PMID: 29462944; PubMed Central PMCID: PMC5855812.

Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A.
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
J Urol. 2018 Dec;200(6):1207-1214.
doi: 10.1016/j.juro.2018.07.035. Epub 2018 Sep 4. PubMed PMID: 30012366.

Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Puhr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, Shariat SF, Kramer G.
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
BJU Int. 2018 Oct;122(4):695-704.
doi: 10.1111/bju.14415. Epub 2018 Jun 20. PubMed PMID: 29802777

Ullrich T, Quentin M, Arsov C, Schmaltz AK, Tschischka A, Laqua N, Hiester A, Blondin D, Rabenalt R, Albers P, Antoch G, Schimmöller L.
Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
J Urol. 2018 Mar;199(3):691-698.
doi: 10.1016/j.juro.2017.09.074. Epub 2017 Sep 20. PubMed PMID: 28941924.

Ullrich T, Quentin M, Schmaltz AK, Arsov C, Rubbert C, Blondin D, Rabenalt R, Albers P, Antoch G, Schimmöller L.
Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate.
Eur Radiol. 2018 Jan;28(1):17-23.
doi: 10.1007/s00330-017-4940-7. Epub 2017 Jul 7. PubMed PMID: 28687912.

Ullrich T, Schimmöller L, Oymanns M, Blondin D, Dietzel F, Kirchner J, Arsov C, Rabenalt R, Albers P, Antoch G, Quentin M.
Current Utilization and Acceptance of Multiparametric MRI in the Diagnosis of Prostate Cancer. A Regional Survey.
Rofo. 2018 May;190(5):419-426.
doi: 10.1055/s-0043-118128. Epub 2017 Sep 21. PubMed PMID: 28934811.

Weber L, Schulz WA, Philippou S, Eckardt J, Ubrig B, Hoffmann MJ, Tannapfel A, Kalbe B, Gisselmann G, Hatt H.
Characterization of the Olfactory Receptor OR10H1 in Human Urinary Bladder Cancer.
Front Physiol. 2018 May 16;9:456.
doi: 10.3389/fphys.2018.00456. eCollection 2018. PubMed PMID: 29867524; PubMed Central PMCID: PMC5964926.

Whongsiri P, Pimratana C, Wijitsettakul U, Jindatip D, Sanpavat A, Schulz WA, Hoffmann MJ, Goering W, Boonla C.
LINE-1 ORF1 Protein Is Up-regulated by Reactive Oxygen Species and Associated with Bladder Urothelial Carcinoma Progression.
Cancer Genomics Proteomics. 2018 Mar-Apr;15(2):143-151. PubMed PMID: 29496693; PubMed Central PMCID: PMC5892605.

Ziayee F, Müller-Lutz A, Gross J, Quentin M, Ullrich T, Heusch P, Arsov C, Rabenalt R, Albers P, Antoch G, Wittsack HJ, Schimmöller L.
Influence of arterial input function (AIF) on quantitative prostate dynamic contrast-enhanced (DCE) MRI and zonal prostate anatomy.
Magn Reson Imaging. 2018 Nov;53:28-33.
doi: 10.1016/j.mri.2018.06.004. Epub 2018 Jun 15. PubMed PMID: 29902565.